Key result
The bivalent RSVpreF vaccine maintained efficacy against RSV-associated lower respiratory tract illness with at least three symptoms across two seasons (vaccine efficacy 81.5%; 95% CI 63.3-91.6).
Why the study?
An analysis was conducted in a second RSV season to understand the duration of protection provided by the RSVpreF vaccine.
Does bivalent RSVpreF vaccine prevent RSV-associated lower respiratory tract illness in adults 60 years of age or older?
RCT
Yes
Does bivalent RSVpreF vaccine prevent RSV-associated lower respiratory tract illness in adults 60 years of age or older?
Effect estimate: Vaccine efficacy 81.5% (95% CI 63.3-91.6)
The bivalent RSVpreF vaccine maintains high efficacy against RSV-associated lower respiratory tract illness in older adults across two RSV seasons.
No takes yet. Share an insight, caveat, or question.
Supports RSVpreF vaccination in adults ≥60 years; extends Phase 3 evidence for sustained protection over two seasons.
Walsh et al. (2024) conducted an RCT in RSV-associated lower respiratory tract illness. Bivalent RSVpreF vaccine was evaluated on RSV-associated lower respiratory tract illness with at least two or at least three symptoms (Vaccine efficacy 81.5%, 95% CI 63.3-91.6). The bivalent RSVpreF vaccine maintained efficacy against RSV-associated lower respiratory tract illness with at least three symptoms across two seasons (vaccine efficacy 81.5%; 95% CI 63.3-91.6).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: